Evelyn Partners Asset Management Ltd Sells 2,577 Shares of Thermo Fisher Scientific Inc. $TMO

Evelyn Partners Asset Management Ltd lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 93.2% in the first quarter, Holdings Channel.com reports. The fund owned 187 shares of the medical research company’s stock after selling 2,577 shares during the quarter. Evelyn Partners Asset Management Ltd’s holdings in Thermo Fisher Scientific were worth $92,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $170,000. Raymond James Financial Inc. grew its stake in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after acquiring an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after acquiring an additional 2,262 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Royal Bank Of Canada lifted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday. Finally, Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $617.14.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $558.79 on Tuesday. The company has a 50 day moving average of $496.34 and a two-hundred day moving average of $512.33. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a market cap of $207.66 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 2.51 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the firm posted $4.28 earnings per share. The business’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 25.07 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.